Secondary Logo

Institutional members access full text with Ovid®

Share this article on:

Patient Involvement in Evaluation of Safety in Oral Antineoplastic Treatment

A Failure Mode and Effects Analysis in Patients and Health Care Professionals

Mattsson, Thea Otto, MD, PhD; Lipczak, Henriette, MD; Pottegård, Anton, MSc Pharm, PhD

doi: 10.1097/QMH.0000000000000199
Quality Improvement

Objectives: To identify risks associated with delivery of treatment with oral antineoplastic agents in an outpatient setting and to evaluate additional value and feasibility of engaging patients in a proactive risk analysis.

Methods: We conducted 2 separate but parallel failure mode and effects analyses (FMEAs) among patients and health care professionals (HCPs) at a clinical oncology department in Denmark. Comparative analyses were performed using the FMEA process maps and risk priority numbers (RPNs) as main outcome measures. The FMEAs were augmented by semistructured interviews with HCPs and patients on acceptability and feasibility of FMEAs analyzed using systematic text condensation.

Results: Patients and HCPs found failures in information regarding treatment (cause, aim, and plan) to be of high risk. Also, HCPs found failures in checking for potential interactions to be of high risk. HCPs focused on the in-hospitals procedures, whereas patients identified risks related to both the hospital and the home setting. Both HCPs and patients found participation in the FMEA process meaningful but found the use of RPNs difficult.

Conclusions: Patient engagement in proactive risk analysis using FMEA is acceptable, meaningful, and feasible, with patients providing a different perspective on the risks associated with oral antineoplastic treatment compared with HCPs.

Department of Oncology (Dr Mattsson) and Hospital Pharmacy, Funen (Dr Pottegård), Odense University Hospital, Odense, Denmark; Department of Documentation & Quality, Danish Cancer Society, Copenhagen, Denmark (Dr Lipczak); and Clinical Pharmacology and Pharmacy, Department of Public Health, University of Southern Denmark, Odense, Denmark (Dr Pottegård).

Correspondence: Thea Otto Mattsson, MD, PhD, Department of Clinical Oncology, Odense University Hospital, Sdr Blvd 29, 5000 Odense C, Denmark (thea.otto.mattsson@rsyd.dk).

The authors thank all participants of this study for their willingness to contribute and their frank discussions.

The authors declare no conflicts of interest.

Supplemental digital content is available for this article. Direct URL citations appear in the printed text and are provided in the HTML and PDF versions of this article on the journal's Web site (www.qmhcjournal.com).

© 2019Wolters Kluwer Health | Lippincott Williams & Wilkins